United Kingdom-based Immune Targeting Systems (ITS) showed data from a Phase IIa trial of its candidate, Flunisyn, at the World Vaccine Congress this week.
University of Maryland researchers are developing a new vaccine against H5N1 avian influenza, also known as bird flu, identified by the World Health Organization as a potentially pandemic virus.
Hospira's manufacturing problems have led to supply interruptions and drug shortages, sometimes leaving customers to scramble for alternatives. Now one one of those customers wants to be reimbursed for its trouble.
Low efficacy of this season's flu vaccine highlights the need for vaccinemakers to develop a better, longer-lasting shot. Only 56% of people who received the jab were protected from influenza, the U.S. Centers for Disease Control and Prevention reports, and the elderly were among the least shielded.
Though the United States has made significant progress in the realm of flu vaccines, the country will likely need to wait 5 to 10 years for a universal shot, top federal health officials said.
An unusually widespread flu season--complete with vaccine shortages and high demand--has scientists and vaccine makers working to develop a quickly produced and long-lasting shot. Life Technologies took a step in this direction with the establishment of the Global Influenza Network.
A heightened flu season and a spate of newly approved influenza vaccines have experts wondering what else they can do to mitigate or prevent the seasonal illness. Next up: A universal flu vaccine administered every 5 to 10 years to fight multiple virus strains and eradicate the need for annual shots.
Though the European Medicines Agency declared last October that links between spikes in narcolepsy in European countries and a swine flu vaccine distributed in 2009 are insufficient, some experts still assert that the shot is to blame, and compelling evidence is growing.
Five years after little Protein Sciences first went to the FDA in search of an approval of its innovative flu vaccine, regulators have finally agreed to hit the green light to permit the biotech to start marketing the jab.
As one of the worst flu seasons in a decade sweeps the United States, some flu vaccine and drug manufacturers find themselves in short supply of their products. Still, the high demand offers a welcome financial boost.